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Abstract 
Review on del(4)(q12q12) FIP1L1/PDGFRA, with 
data on clinics, and the genes implicated. 
Identity 
Other names 
Interstitial 4q12 deletion 
FIP1L1/PDGFRA fusion in eosinophilia-associated 
hematologic disorders 
Clinics and pathology 
Disease 
An interstitial deletion del(4)(q12q12) generating a 
FIP1L1-PDGFRA fusion gene is observed in 
diverse eosinophilia-associated hematologic 
disorders like hyperseosinophilic syndrome (HES), 
systemic mastocytosis (SM) and chronic 
eosinophilic leukemia (CEL).  
The updated WHO classification distinguishes 
these myeloid and lymphoid neoplasms with 
eosinophilia and abnormalities of PDGFRA, 
PDGFRB or FGFR1 as chronic eosinophilic 
leukemia (CEL) not otherwise specified (NOS); 
lymphocyte-variant hypereosinophilia and 
idiopathic hypereosinophilic syndrome (HES) 
(Gleich and Leiferman, 2009; Gotlib, 2014). 
Occasionally, the FIP1L1-PDGFRA fusion can be 
identified in patients with acute myeloid leukemia 
or B-cell or T-cell acute lymphoblastic leukemia or 
lymphoblastic lymphoma and sporadically in 
myeloid sarcoma (Metzgeroth et al., 2007; Tang et 
al., 2012). 
Phenotype/cell stem origin 
FIP1L1-PDGFRA rearrangement has been found in 
a variety of cell lineages (neutrophils, monocytes, 
eosinophils, CD34+ cells, mast cells and even 
lymphoid) consistent with an origin in an 
hematopoietic stem cells or early progenitors 
progenitor (Gotlib and Cools, 2008). 
Etiology 
The cause of FIP1L1-PDGFRA associated 
hypereosinophilic syndrome is unknown as well as 
its association with predominantly male sex. 
Epidemiology 
FIP1L1-PDGFRA (+) eosinophilias are considered 
to be rare entities; however the incidence rates for 
molecularly defined eosinophilic disorders are not 
known.  
Data support a FIP1L1-PDGFRA fusion incidence 
of approximately 10-20% among patients 
presenting with idiopathic hypereosinophilia 
(Gotlib and Cools, 2008).  
However, in unselected patients with eosinophilia 
only 3% of were found to carry the FIP1L1-
PDGFRA fusion (Pardanani et al., 2004; Pardanani 
et al., 2006). 
Clinics 
Characteristic feature of PDGFRA-associated 
disorders is eosinophil overproduction in the bone 
marrow resulting in increased blood eosinophils. 
Marked and sustained eosinophilia eventually leads 
to eosinophilic infiltration and functional damage of 
peripheral organs, most commonly the heart, skin, 
lungs, or nervous system.  
Patients often present with hepatomegaly or 
splenomegaly hypercellular bone marrows with 
myelofibrosis, increased number of neutrophils 
and/or mast cells.  
Serum B12 and tryptase levels may be significantly 
elevated (Vandenberghe et al., 2004; Gleich and 
Leiferman, 2009). 
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Figure 1. Detection of the del(4)(q12q12) by fluorescence in situ hybridization using the LSI FIP1L1-CHIC2-PDGFRA Triple-
Color, split assay (Abott Molecular; Vysis, Denver US) on a metaphase (A) and interphases (B). This probe is designed as a 
deletion probe when absence of the CHIC2 region is observed as loss of a red signal (arrows) from the co-localized green/blue 
signal, indicative of the presence of this specific deletion that leads to FIP1L1-PDGFRA fusion on one of the chromosomes 4. 
 
Treatment 
FIP1L1-PDGFRA associated hypereosinophilic 
disorders are sensitive to treatments with tyrosine 
kinase inhibitors such as imatinib mesylate 
(imatinib). Imatinib is the first-line therapy for 
patients with abnormalities of PDGFRA; however 
chronic eosinophilic leukemia with FIP1L1-
PDGFRA is likely to be responsive also to 
dasatinib, nilotinib, sorafenib and midostaurin 
(PKC412) (Lierman et al., 2009). 
Prognosis 
Patients with hypereosinophilic syndrome 
historically carried a poor prognosis before the 
successful therapeutic application of tyrosine kinase 
inhibitors. Targeted therapy has dramatically 
changed the prognosis of patients carrying the 
FIP1L1-PDGFRA fusion which show an excellent 
response to low-dose imatinib. Treatment with low-
dose imatinib (100 mg/d) produced complete and 
durable responses with normalization of 
eosinophilia. Importantly, these remissions appear 
to be durable with continued imatinib therapy in a 
high proportion of patients (Barraco et al., 2014).  
Acquired resistance is exceedingly rare; the T674I 
mutation in the ATP-binding region of PDGFRA 
(mutation of the threonine at position 674) is the 
most common. Interestingly, the T674I mutation 
that is analogous to the T315I mutation of BCR-
ABL1 in chronic myeloid leukemia also confers 
imatinib resistance (Cools et al., 2003; Jain et al., 
2013). For refractory disease, interferon-a may be a 
therapeutic option. 
Cytogenetics 
Note 
The cryptic interstitial deletion on chromosome 
band 4q12 leading to FIP1L1-PDGFRA fusion is 
quite unique as it is generated by a cryptic 
chromosomal deletion, rather than a translocation 
(Gotlib and Cools, 2008). 
Cytogenetics morphological 
Because FIP1L1-PDGFRA is generated by a 
cryptic deletion at 4q12 that is only 800 kb in size, 
it remains undetected with standard cytogenetics. 
Therefore; most of the patients with the fusion have 
an apparently normal karyotype.  
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Figure 2. Model of the involvement of PDGFRA-FIP1L1 fusion gene in the pathogenesis of hypereosinophilic disorders. A cryptic 
deletion on chromosome 4 brings the normally distant PDGFRA and FIP1L1 genes into close proximity, generating a fused gene. 
Fusion of FIP1L1 to the PDGFRA protein results in a constitutive kinase activation of PDGFRA with transforming potential that 
may lead to eosinophilic disorders. Administration of the kinase inhibitor such as imatinib is highly effective molecularly targeted 
therapy for this group of patients. 
 
Occasional patients have had a chromosomal 
rearrangement with a 4q12 breakpoint, such as 
t(1;4)(q44;q12), which ultimately led to the 
identification of the fusion gene or t(4;10)(q12;p11) 
(Cools et al., 2003; Gotlib et al., 2004). 
Cytogenetics molecular 
One of the best techniques to detect the presence of 
the FIP1L1-PDGFRA fusion gene is using triple-
color FISH probes hybridizing to the region 
between the FIP1L1 and PDGFRA genes 
incorporating the CHIC2 (cysteine-rich 
hydrophobic domain 2) gene.  
A more sensitive technique is the use of reverse-
transcription polymerase chain reaction (RT-PCR) 
(La Starza et al., 2005) or quantitative RT-PCR 
methods, used for monitoring therapy response to 
tyrosine kinase inhibitors. 
Variants 
A few other variant PDGFRA fusion genes have 
been described: t(4;22)(q12;q11)/BCR-PDGFRA, 
t(2;4)(p24;q12)/STRN-PDGFRA, 
ins(9;4)(q33;q12q25)/CDK5RAP2-PDGFRA, 
complex karyotype/KIF5B-PDGFRA and 
t(4;12)(q12;p13)/ETV6-PDGFRA (Gleich and 
Leiferman, 2009). The involvement of FIP1L1 was 
described in a t(4;17)(q12;q21) with FIP1L1/RARA 
fusion in a patient with juvenile myelomonocytic 
leukemia (Shah et al., 2014). 
Genes involved and 
proteins 
PDGFRA 
Location 
4q12 
Note 
platelet-derived growth factor receptor, alpha 
polypeptide 
DNA/RNA 
PDGFRA contains 23 exons spanning about 65 kb. 
The gene encodes a cell surface tyrosine kinase 
receptor. An important paralog of PDGFRA is 
FLT4. 
Protein 
1089 amino acids; PDGFA belongs to a family of 
receptor tyrosine kinases that include PDGFRA and 
PDGFRB that have intracellular tyrosine kinase 
activity that binds members of the platelet-derived 
growth factor family.  
It plays an essential role in the regulation of 
embryonic development, organ development, 
wound healing, angiogenesis and chemotaxis; role 
in the differentiation of bone marrow-derived 
mesenchymal stem cells, cell proliferation and 
survival (Hsieh et al., 1991; Kawagishi et al., 
1995).  
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Figure 3. Generation of the FIP1L1-PDGFRA fusion protein. Splicing of FIP1L1 exons to the truncated exon 12 of PDGFRA 
results in disruption of the autoinhibitory juxtamembrane domain of PDGFRA. FIP1L1-PDGFRA expression became under 
control of the ubiquitous FIP1L1 promoter leading to dysregulated tyrosine kinase activity. NLS indicates nuclear localization 
signal; TM, transmembrane region; JM, juxtamembrane region. Adapted from Cools et al., 2003; Vandenberghe et al., 2004; 
Gotlib and Cools, 2008; Gleich and Leiferman, 2009. 
 
PDGFRA is involved in the pathogenesis of various 
disorders, including cancer. 
FIP1L1 
Location 
4q12 
Note 
factor interacting with PAPOLA and CPSF1 
DNA/RNA 
4 distinct isoforms; alternative splicing results in 
multiple transcript variants. 
Protein 
pre-mRNA 3'-end-processing factor; 520 amino 
acids. FIP1 belongs to the FIP1 family. It has RNA 
binding protein kinase activity as a component of 
cleavage and polyadenylation specificity factor 
(CPSF) complex. Plays a key role in 
polyadenylation of the 3' end of mRNA precursors 
and in the transcriptional process. FIP1L1 is 
predicted to be under the control of a ubiquitous 
promoter. Many additional functions of the protein 
are largely unknown (Gotlib et al., 2004). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
In-frame fusion of the 5' part of FIP1L1 to the 3' 
part of PDGFRA. 
The generation of the fusion between the 5' part of 
the FIP1L1 gene and the 3' part of the PDGFRA 
gene is the consequence of a deletion of the 800 kb 
genomic region between the two genes on 4q12. 
Several genes between FIP1L1 and PDGFRA have 
been identified: LNX1 (the ligand of numb-protein 
X 1), the hypothetical protein LOC402176 
(LOC402176), CHIC2 (cysteine-rich hydrophobic 
domain 2) and the homeobox protein GSH-2 
(GSH2). While breakpoints in FIP1L1 are scattered 
over a region of 40 kb (introns 7-10), breakpoints 
within the PDGFRA gene are tightly clustered and 
are always within exon 12, encoding the 
juxtamembrane region (JM). Truncations of the JM 
region invariably results in the removal of part of 
the juxtamembrane domain and generation of in-
frame fusion transcripts (Cools et al., 2003; 
Vandenberghe et al., 2004). Rarely, FIP1L1 
breakpoint is located outside of the common 
FIP1L1 breakpoint regions (Lambert et al., 2007). 
Transcript 
5'FIP1L1-3'PDGFRA; no reciprocal PDGFRA-
FIP1L1 fusion gene can be detected as the fusion is 
the consequence of an interstitial deletion and not a 
reciprocal translocation.  
As the normal splice site at 5' part of exon 12 of 
PDGFRA is deleted, cryptic splice sites in FIP1L1 
introns or within exon 12 of PDGFRA are used to 
generate in-frame FIP1L1-PDGFRA fusions 
(Gotlib and Cools, 2008). 
Fusion protein 
Description 
The FIP1L1-PDGFRA protein is made by the first 
twelve exons of FIP1L1 and from truncated exon 
12 (containing the last 17 amino acids) to exon 23 
of PDGFRA. The FIP1L1-PDGFRA fusion protein 
is a constitutively activated tyrosine kinase that 
joins the first 233 amino acids of FIP1L1 to the last 
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523 amino acids of PDGFRA (Gotlib and Cools, 
2008). 
Oncogenesis 
An interstitial deletion on chromosome 4q12 site 
brings the normally distant PDGFRA and FIP1L1 
genes into proximity generating a hybrid FIP1L1-
PDGFRA gene. In the translated protein, the 
juxtamembrane domain of PDGFRA that is known 
to serve an autoinhibitory function is truncated and 
became under control of the ubiquitous FIP1L1 
promoter resulting in its constitutive kinase 
activation. Dysregulated tyrosine kinase activity 
leads to proliferation of multiple myeloid lineages 
via activation of several pathways. The STAT1/3 
and STAT5 (signal transducers and activators of 
transcription) transcriptional factors appear to be 
activated either directly or via interaction with JAK 
(Janus activated kinase) pathways. However, the 
exact mechanism, by which FIP1L1-PDGFR affects 
the development of HES/CEL and why 
preferentially affects eosinophils remains unclear. 
Mouse models of FIP1L1-PDGFRA induced 
disease revealed that FIP1L1-PDGFRA expression 
induce a myeloproliferative phenotype without 
eosinophilia. Therefore, it is likely that FIP1L1-
PDGFRA expression alone is not sufficient to cause 
eosinophilia and additional processes such as 
cooperation with nuclear factor-kB and IL-5 
signaling are required in differentiation towards the 
eosinophil lineage (Yamada et al., 2006; Montano-
Almendras et al., 2012). 
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